| Title: | Lung cancer biomarker testing : perspective from Europe |
|---|
| Authors: | ID Thunnissen, Erik (Author)
ID Weynand, Birgit (Author)
ID Udovicic-Gagula, Dalma (Author)
ID Brčić, Luka (Author)
ID Szolkowska, Malgorzata (Author)
ID Hofman, Paul (Author)
ID Smojver-Ježek, Silvana (Author)
ID Anttila, Sisko (Author)
ID Calabrese, Fiorella (Author)
ID Kern, Izidor, Klinika Golnik (Author) |
|---|
| Files: |  PDF - Presentation file, download (1,80 MB)
MD5: 08500071FD4E2273A0DACAEECA7E7FDB
 URL - Source URL, visit http://tlcr.amegroups.com/article/view/40413/pdf
|
|---|
| Language: | English |
|---|
| Typology: | 1.02 - Review Article |
|---|
| Organization: |  UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
|---|
| Abstract: | A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future. |
|---|
| Keywords: | lung neoplasms -- diagnosis -- therapy -- Europe, lung cancer, predictive testing |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Place of publishing: | Kitajska |
|---|
| Publisher: | AME Publishing |
|---|
| Year of publishing: | 2020 |
|---|
| Number of pages: | str. 887-897 |
|---|
| Numbering: | Vol. 9, iss. 3 |
|---|
| PID: | 20.500.12556/DiRROS-12421  |
|---|
| UDC: | 616-006 |
|---|
| ISSN on article: | 2226-4477 |
|---|
| COBISS.SI-ID: | 28071683 |
|---|
| Copyright: | © Translational Lung Cancer Research |
|---|
| Note: | Nasl. z nasl. zaslona;
Soavtor iz Slovenije: Izidor Kern;
Opis vira z dne 11. 9. 2020;
|
|---|
| Publication date in DiRROS: | 21.09.2020 |
|---|
| Views: | 2212 |
|---|
| Downloads: | 1235 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
